New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
12:55 EDTRCPT, RCPT, NVS, NVS, BIIB, BIIBSummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen and Biotech Analyst Werther discuss novel drugs for Multiple Sclerosis, including drugs manufactured by RCPT, NVS and BIIB, on an Analyst/Industry conference call to be held on May 21 at 1:30 pm.
News For RCPT;NVS;BIIB From The Last 14 Days
Check below for free stories on RCPT;NVS;BIIB the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
16:07 EDTNVSAnacor announces commercial launch of KERYDIN topical solution in U.S.
Subscribe for More Information
07:21 EDTBIIBEBD Group to hold a conference
Subscribe for More Information
September 16, 2014
07:31 EDTNVSEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
12:02 EDTRCPTReceptos price target raised to $80 from $63 at Wedbush
Subscribe for More Information
10:59 EDTRCPTReceptos price target raised to $77 from $60 at Leerink
Subscribe for More Information
08:01 EDTBIIBAlnylam names Karen Anderson as SVP, Chief Human Resources Officer
Subscribe for More Information
07:48 EDTRCPTReceptos price target raised to $75 from $58 at Credit Suisse
Credit Suisse raised Receptos' price target to $75 citing increased clarity on RPC1063's potential differentiated profile following presentation of further RADIANCE Ph II data. Share are Outperform rated.
07:27 EDTNVSIBC Life Sciences to hold a conference
Subscribe for More Information
07:21 EDTNVSHeart Failure Society of America to hold annual meeting
Subscribe for More Information
September 12, 2014
07:32 EDTBIIBBiogen, AbbVie announce ZINBRYTA DECIDE Phase 3 study results
Biogen (BIIB) and AbbVie (ABBV) announced the full results from the Phase 3 DECIDE clinical trial, which show ZINBRYTA, dosed subcutaneously once a month, demonstrated a statistically significant improvement in reducing disease activity in people with relapsing-remitting multiple sclerosis compared to AVONEX. These results are being presented at the Sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis. Patients on ZINBRYTA demonstrated a statistically significant 45% reduction in annualized relapse rate compared to patients treated with AVONEX. Based on the efficacy and safety data from the ZINBRYTA clinical development program, Biogen Idec and AbbVie plan to file marketing applications for ZINBRYTA with regulatory authorities during 1H15.
05:18 EDTNVSNovartis announces new data confirms high efficacy of Gilenya in achieving NEDA
Novartis announced new analyses presented at the Joint ACTRIMS-ECTRIMS Meeting in Boston, USA, which confirmed the high efficacy of Gilenya in achieving 'no evidence of disease activity', or NEDA, in people with relapsing-remitting multiple sclerosis, or RRMS, across four key disease measures - relapses, MRI lesions, brain shrinkage and disability progression. Specifically, patients taking Gilenya had a more than four-times greater likelihood of achieving NEDA across these four key measures. NEDA is currently defined as having no relapses, MRI lesions and disability progression. These new analyses from the phase III FREEDOMS and FREEDOMS II trials reinforce the value of including brain shrinkage to the definition of NEDA. The inclusion of brain shrinkage into the NEDA definition would allow physicians to obtain a more complete assessment of a patient's disease, including the underlying damage in MS.
September 11, 2014
07:31 EDTBIIBBiogen announces 5-year results from TECFIDERA ENDORSE Phase 3 study
Subscribe for More Information
07:31 EDTBIIBBiogen announces new data from Plegridy Phase 3 ADVANCE trial
Biogen Idec announced new data from the second year of its Phase 3 ADVANCE clinical trial that show the positive treatment effects of PLEGRIDY were maintained in people with relapsing forms of multiple sclerosis beyond the first year of the study. These results were presented at the sixth Triennial Joint Meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis in Boston. Post-hoc analyses from the two-year, Phase 3 ADVANCE clinical trial confirm that PLEGRIDY’s positive effects on reducing disease activity and disability progression were maintained in year two of the study. A significantly higher proportion of patients taking PLEGRIDY during both years of the study experienced no evidence of disease activity – defined as the absence of clinical and MRI disease activity over two years of treatment – compared to those who switched to PLEGRIDY from placebo. Also, those treated with PLEGRIDY for both years of the study had significant reductions in the risk of 24-week confirmed disability progression compared to patients treated with placebo during the first year. In addition, new data from the second year of ADVANCE show that patients who took PLEGRIDY throughout the study experienced statistically significant improvements in clinical and MRI outcomes – including annualized relapse rate, risk of relapse, risk of 24-week confirmed disability progression, and number of brain lesions – when compared to those who switched to PLEGRIDY after taking placebo for the first year. This new data also showed that the safety profile of PLEGRIDY was consistent between years one and two of the study.
September 10, 2014
16:19 EDTRCPTOn The Fly: Closing Wrap
Subscribe for More Information
15:05 EDTRCPTReceptos surges after abstracts for RADIANCE trial posted
Shares of drugmaker Receptos (RCPT) are sharply higher after an abstract for the company's Phase 2 portion of its RADIANCE trial of RPC1063 in Relapsing Multiple Sclerosis, or RMS, were posted to the site of the European Committee for Treatment and Research in Multiple Sclerosis, or ECTRIMS. WHAT'S NEW: This morning, Receptos announced that data from the Phase 2 portion of RADIANCE, the company's Phase 2/3 trial of RPC1063 in RMS, will be reviewed in a late breaker oral podium presentation at MS Boston on September 13. MS Boston is a joint meeting of ECTRIMS and ACTRIMS, which is the U.S. and Canadian counterpart to ECTRIMS. ANALYST REACTION: Analysts at BMO Capital said the RADIANCE data confirm differentiation of the drug. The firm has an Outperform rating and $72 price target on the stock. Meanwhile, Leerink said that the full RADIANCE data shows a 53% annualized relapse reduction and supports a "highly differentiated safety profile" for the drug. Leerink has an Outperform rating and $60 price target on shares of Receptos. PRICE ACTION: In late afternoon trading, shares of Receptos were up $11.29, or 24%, to $58.34.
12:50 EDTRCPTReceptos to host conference call
Subscribe for More Information
05:17 EDTNVSNovartis Gilenya data confirms reducing brain shrinkage matter for MS patients
Subscribe for More Information
September 9, 2014
07:55 EDTNVSOphthotech earlier than expected Novartis payment positive, says Oppenheimer
After Ophthotech (OPHT) received a $50M Phase 3 enrollment payment from Novartis (NVS) earlier than expected, Oppenheimer thinks the payment highlights an underappreciated stock driver for Opthotech, and demonstrates that recent suggestions of Phase 3 enrollment timelines possibly slipping are unwarranted. The firm believes the company is executing well on the Fovista Phase 3 program and keeps an Outperform rating on the stock.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use